Unclaimed brand
BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing patient-friendly compounds to treat neuro-psychiatric and neurological disorders. Our vision is to take the fear out of psychedelics by producing non-hallucinogenic medicines that will be the solutions to treat the wide range of unmet mental health conditions like anxiety, depression, PTSD, & migraine
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#00AC9C
Persian Green
0, 172, 156
174, 100, 34
100, 0, 9, 33
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#515151
Emperor
81, 81, 81
0, 0, 32
0, 0, 0, 68
BetterLife Pharma is an emerging biotechnology company developing and commercializing patient-friendly medicines for neuropsychiatric and neurological disorders. Its mission is to expand treatment options for people facing unmet mental health needs, with a particular focus on medicines intended to provide therapeutic benefits without unwanted hallucinogenic effects.
The company’s lead candidate, BETR-001, is a second-generation derivative of lysergic acid diethylamide (LSD). BetterLife describes it as a non-hallucinogenic compound designed to mimic LSD’s projected therapeutic properties while avoiding hallucinations. The candidate is being explored for conditions including treatment-resistant depression, post-traumatic stress disorder, cluster headaches, and other migraine and headache disorders. These are potential uses under development, not established treatments.
BetterLife emphasizes science- and evidence-driven research, efficient development, and improving access to future therapies. Its approach aims to offer alternatives in areas where patients and healthcare providers need more options. Based in Vancouver, British Columbia, BetterLife Pharma is publicly traded under the symbols BETR on the CSE and BETRF on the OTCQB.
Non-hallucinogenic psychedelic-derived therapeutics
Neuroplastogen drug development
LSD-derivative medicines
Cluster headache therapeutics
Psychiatric drug development
